<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Ann Nucl Med</journal-id><journal-id journal-id-type="iso-abbrev">Ann Nucl Med</journal-id><journal-title-group><journal-title>Annals of Nuclear Medicine</journal-title></journal-title-group><issn pub-type="ppub">0914-7187</issn><issn pub-type="epub">1864-6433</issn><publisher><publisher-name>Springer Japan</publisher-name><publisher-loc>Tokyo</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24363079</article-id><article-id pub-id-type="pmc">4483188</article-id><article-id pub-id-type="publisher-id">796</article-id><article-id pub-id-type="doi">10.1007/s12149-013-0796-3</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Diagnosis of dementia with Lewy bodies: diagnostic performance of combined <sup>123</sup>I-IMP brain perfusion SPECT and <sup>123</sup>I-MIBG myocardial scintigraphy</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Sakamoto</surname><given-names>Fumi</given-names></name><address><phone>+81-09-63735261</phone><fax>+81-09-63624330</fax><email>fumisaka@kumamoto-u.ac.jp</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Shiraishi</surname><given-names>Shinya</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Yoshida</surname><given-names>Morikatsu</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Tomiguchi</surname><given-names>Seiji</given-names></name><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Hirai</surname><given-names>Toshinori</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Namimoto</surname><given-names>Tomohiro</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Hashimoto</surname><given-names>Mamoru</given-names></name><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>Ikeda</surname><given-names>Manabu</given-names></name><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>Uetani</surname><given-names>Hiroyuki</given-names></name><xref ref-type="aff" rid="Aff4"/></contrib><contrib contrib-type="author"><name><surname>Yamashita</surname><given-names>Yasuyuki</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><label/>Department of Diagnostic Radiology, Graduate School of Life Sciences, Kumamoto University, 1-1-1 Honjyo, Kumamoto, 860-0821 Japan </aff><aff id="Aff2"><label/>Department of Diagnostic Medical Imaging, School of Health Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan </aff><aff id="Aff3"><label/>Department of Neuropsychiatry, Graduate School of Life Sciences, Kumamoto University, Kumamoto, Japan </aff><aff id="Aff4"><label/>Department of Radiology, Japanese Red Cross Kumamoto Hospital, Kumamoto, Japan </aff></contrib-group><pub-date pub-type="epub"><day>21</day><month>12</month><year>2013</year></pub-date><pub-date pub-type="pmc-release"><day>21</day><month>12</month><year>2013</year></pub-date><pub-date pub-type="ppub"><year>2014</year></pub-date><volume>28</volume><issue>3</issue><fpage>203</fpage><lpage>211</lpage><history><date date-type="received"><day>22</day><month>7</month><year>2013</year></date><date date-type="accepted"><day>5</day><month>12</month><year>2013</year></date></history><permissions><copyright-statement>&#x000a9; The Japanese Society of Nuclear Medicine 2013</copyright-statement></permissions><abstract id="Abs1"><sec><title>Objective</title><p>
We assessed the value of combining <sup>123</sup>I-IMP brain perfusion SPECT and <sup>123</sup>I-MIBG myocardial scintigraphy for the discrimination of dementia with Lewy bodies (DLB) from other types of dementia.
</p></sec><sec><title>Methods</title><p>We subjected 252 consecutive patients with clinically suspected DLB to both <sup>123</sup>I-IMP brain perfusion SPECT and <sup>123</sup>I-MIBG myocardial scintigraphy. Patients with Parkinson&#x02019;s disease were included. The 252 patients were randomly assigned to an estimation (<italic>n</italic>&#x000a0;=&#x000a0;152) or a validation group (<italic>n</italic>&#x000a0;=&#x000a0;100). Using univariate analysis, we first analyzed the relationship between various variables and the presence or absence of DLB in estimation group and then proceeded to multivariate analysis to obtain a combined index that predicted the likelihood of DLB. The diagnostic value of the index was assessed by calculating the area under the receiver operating characteristic (ROC) curve (AUC) with the cutoff value selected from the ROC curve. We then tested the predictive accuracy of the index in validation group.
</p></sec><sec><title>Results</title><p>The combined index was an arithmetic expression that combined the age, early <sup>123</sup>I-MIBG heart-to-mediastinum uptake (E-H/M) ratio, and the parietal lobe hypoperfusion score. Values for the AUC of the combined index, the E-H/M ratio, the parietal lobe hypoperfusion score, and the patient age in validation group were 0.95, 0.90, 0.72, and 0.73, respectively. There was a significant difference in the AUC of the combined index among other indices (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.05). The sensitivity, specificity, and accuracy of the combined index for a diagnosis of probable DLB in validation group were 88, 87, and 87&#x000a0;%, respectively.</p></sec><sec><title>Conclusions</title><p>The combinational diagnosis based on <sup>123</sup>I-IMP brain perfusion SPECT, <sup>123</sup>I-MIBG myocardial scintigraphy, and the patient age is a simple and reliable means for predicting probable DLB.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Dementia with Lewy bodies</kwd><kwd><sup>123</sup>I-IMP brain perfusion SPECT</kwd><kwd><sup>123</sup>I-MIBG myocardial scintigraphy</kwd><kwd>Combined index</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Japanese Society of Nuclear Medicine 2014</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p>Dementia with Lewy bodies (DLB), Alzheimer&#x02019;s disease (AD), and vascular dementia (VaD) are the most common types of dementia. Approximately, 20&#x02013;30&#x000a0;% of elderly Japanese manifest DLB. Its symptoms are progressive deterioration of cognitive function, fluctuating cognitive impairment, Parkinsonism, recurring specific hallucinations, falls, and syncope [<xref ref-type="bibr" rid="CR1">1</xref>]. Patients with DLB tend to present with serious behavioral and psychological symptoms of dementia (BPSD) which reduce their quality of life and present problems for caregivers [<xref ref-type="bibr" rid="CR2">2</xref>]. DLB progresses more rapidly than other dementing disorders and these patients have a poor prognosis with worsening cognitive impairment and Parkinsonism.</p><p>Patients with DLB are hypersensitive to drugs, some manifest a hypersensitive reaction to antipsychotic or antidepressant drugs resulting in symptom exacerbation. Cholinesterase inhibitors (ChEIs) are effective and regarded as the first-line therapy for BPSD; however, in patients with AD, they may elicit adverse reactions such as the promotion of excitement [<xref ref-type="bibr" rid="CR3">3</xref>]. While an accurate differential diagnosis is necessary, there are few specific symptoms in the early stages of DLB and symptoms overlap with other dementing disorders. Consequently, it is often difficult to arrive at a correct diagnosis based only on the clinical presentation whose reported sensitivity and specificity are 22&#x02013;83 and 79&#x02013;100&#x000a0;%, respectively [<xref ref-type="bibr" rid="CR4">4</xref>&#x02013;<xref ref-type="bibr" rid="CR7">7</xref>].</p><p>Diagnostic imaging is thought to improve the diagnostic performance. Current imaging modalities for DLB are <sup>123</sup>I-metaiodobenzylguanidine (MIBG) cardiac scintigraphy, computed tomography (CT), magnetic resonance imaging (MRI), single photon emission computed tomography (SPECT), and positron emission tomography (PET) [<xref ref-type="bibr" rid="CR8">8</xref>]. To our knowledge, only Hanyu et al. [<xref ref-type="bibr" rid="CR9">9</xref>] and Tateno et al. [<xref ref-type="bibr" rid="CR10">10</xref>] compared the usefulness of <sup>123</sup>I-IMP brain perfusion SPECT- and <sup>123</sup>I-MIBG myocardial scintigraphy studies to differentiate between DLB and AD.</p><p>Many patients suspected of having DLB based on imaging findings and/or their clinical presentation also suffer from comorbidities such as Parkinson&#x02019;s disease (PD), progressive supranuclear palsy (PSP), multiple system atrophy (MSA), corticobasal degeneration (CBD), and AD. Therefore, we conducted a retrospective study of patients with various types of dementia (including PD) who underwent both <sup>123</sup>I-IMP brain perfusion SPECT- and <sup>123</sup>I-MIBG myocardial scintigraphy studies to evaluate the usefulness of these imaging studies for the diagnosis of DLB.</p></sec><sec id="Sec2" sec-type="methods"><title>Patients and methods</title><sec id="Sec3"><title>Subjects</title><p>Our study was approved by our institutional ethics board. Patient informed consent was waived due to its retrospective, purely observational nature.</p><p>Between January 2007 and December 2012, 270 patients with clinically suspected DLB underwent both <sup>123</sup>I-IMP brain perfusion SPECT and <sup>123</sup>I-MIBG myocardial scintigraphy studies at Kumamoto University Hospital. Based on criteria promulgated by the Consortium on DLB International Workshop [<xref ref-type="bibr" rid="CR11">11</xref>], 72 patients (31 men, 41 women; mean age&#x000a0;&#x000b1;&#x000a0;SD, 77.1&#x000a0;&#x000b1;&#x000a0;6.0&#x000a0;years; range 56&#x02013;89&#x000a0;years) had probable DLB, 18 (5 men, 13 women; mean age 77.9&#x000a0;&#x000b1;&#x000a0;4.8&#x000a0;years; range 70&#x02013;87&#x000a0;years) had possible DLB, and 180 (68 men, 112 women; mean age 71.8&#x000a0;&#x000b1;&#x000a0;9.3&#x000a0;years; range 34&#x02013;92&#x000a0;years) had without DLB. There were 25 patients with PD. Patients with congestive heart failure or taking antipsychotic drugs (tricyclic antidepressants, reserpine) that would affect the results of <sup>123</sup>I-MIBG myocardial scintigraphy were excluded, while patients with well-controlled diabetes or hypertension treated with small doses of ACE inhibitors or &#x003b2; blockers were included although their <sup>123</sup>I-MIBG myocardial scintigraphy findings may have been affected [<xref ref-type="bibr" rid="CR12">12</xref>]. The diagnoses of the 180 patients with without DLB are shown in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>. We excluded patients with possible DLB because both DLB and other types of dementia were included in this category.<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Diagnoses of 252 patients included in this study</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Estimation group (<italic>n</italic>&#x000a0;=&#x000a0;152)</th><th align="left">Validation group (<italic>n</italic>&#x000a0;=&#x000a0;100)</th></tr></thead><tbody><tr><td align="left">Probable DLB (<italic>n</italic>&#x000a0;=&#x000a0;72)</td><td char="." align="char" rowspan="2">46</td><td char="." align="char" rowspan="2">26</td></tr><tr><td align="left">Without DLB (<italic>n</italic>&#x000a0;=&#x000a0;180)</td></tr><tr><td align="left">&#x000a0;AD</td><td char="." align="char">23</td><td char="." align="char">8</td></tr><tr><td align="left">&#x000a0;PD</td><td char="." align="char">14</td><td char="." align="char">11</td></tr><tr><td align="left">&#x000a0;PSP</td><td char="." align="char">13</td><td char="." align="char">5</td></tr><tr><td align="left">&#x000a0;MSA</td><td char="." align="char">7</td><td char="." align="char">3</td></tr><tr><td align="left">&#x000a0;CBD</td><td char="." align="char">6</td><td char="." align="char">5</td></tr><tr><td align="left">&#x000a0;VaD</td><td char="." align="char">6</td><td char="." align="char">2</td></tr><tr><td align="left">&#x000a0;iNPH</td><td char="." align="char">5</td><td char="." align="char">1</td></tr><tr><td align="left">&#x000a0;RBD</td><td char="." align="char">4</td><td char="." align="char">4</td></tr><tr><td align="left">&#x000a0;Others</td><td char="." align="char">28</td><td char="." align="char">35</td></tr></tbody></table><table-wrap-foot><p>
<italic>AD</italic> Alzheimer&#x02019;s disease, <italic>PD</italic> Parkinson&#x02019;s disease, <italic>PSP</italic> progressive supranuclear palsy, <italic>MSA</italic> multiple system atrophy, <italic>CBD</italic> corticobasal degeneration, <italic>VaD</italic> vascular dementia, <italic>iNPH</italic> idiopathic normal pressure hydrocephalus, <italic>RBD</italic> REM sleep behavior disorder</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec4"><title><sup>123</sup>I-IMP brain perfusion SPECT</title><p>We used a two-head gamma camera (Millennium VG, GE) equipped with a low-energy general-purpose collimator. <sup>123</sup>I-IMP brain perfusion SPECT was performed for approximately 20&#x000a0;min (continuous mode, 2.5&#x000a0;min/rotation, 12 rotations, 64&#x000a0;&#x000d7;&#x000a0;64 matrix) immediately after the intravenous (i.v.) injection of <sup>123</sup>I-IMP (167&#x000a0;MBq in 1.5&#x000a0;ml). The energy peak was set at 157&#x000a0;keV with a 20&#x000a0;% energy window. Transaxial images were reconstructed with filtered back projection using a Butterworth filter. An order-10 Butterworth filter (cut-off 0.45) was used for post-reconstruction. The reconstructed slice thickness was 2.95&#x000a0;mm. SPECT image was reconstructed with a uniform attenuation correction using Chang&#x02019;s methods; we did not correct for scatter. The reconstructed <sup>123</sup>I-IMP SPECT images were analyzed with Neurostat/(3D-SSP) using image-analysis software (iSSP version 3.5) [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]; data were normalized to the mean global activity. Further analysis was with stereotactic extraction estimation (SEE) software [<xref ref-type="bibr" rid="CR15">15</xref>]. Using the SEE method, we divided the whole brain into segments (level 2, lobe level-; level 3, gyrus level classification) and assessed the severity of hypoperfusion in the frontal-, parietal-, temporal-, and occipital lobe, the precentral and postcentral gyrus, the precuneus, parahippocampus, anterior and posterior cingulate, and the uncus.</p></sec><sec id="Sec5"><title><sup>123</sup>I-MIBG cardiac scintigraphy</title><p>Planar scans were acquired using a two-head gamma camera (Millennium VG, GE) equipped with a medium-energy general-purpose collimator. The patients underwent <sup>123</sup>I-MIBG scintigraphy during quiet respiration without breath-holding within 1&#x02013;4&#x000a0;weeks before or after <sup>123</sup>I-IMP SPECT.</p><p><sup>123</sup>I-MIBG anterior planar images were obtained 15&#x000a0;min and 3&#x000a0;h (early and delayed images, respectively) after the i.v. injection of <sup>123</sup>I-MIBG. (111&#x000a0;MBq, 3&#x000a0;mCi). The planar-image acquisition time was 5&#x000a0;min, the matrix size was 256&#x000a0;&#x000d7;&#x000a0;256, and the energy window was set at 157&#x000a0;keV (&#x000b1;10&#x000a0;%). The pixel size of the planar images was 1.64&#x000a0;mm. Using the region of interest (ROI) method, we calculated the early and delayed <sup>123</sup>I-MIBG heart-to-mediastinum uptake (H/M) ratios on anterior views of the planar images. An irregular circular ROI was manually drawn on the left ventricle and a square ROI was placed in the upper mediastinum area.</p></sec><sec id="Sec6"><title>Statistical analysis</title><p>Our objective was to differentiate patients with probable DLB from patients without DLB using a combination of variables. Diabetes, treatment with ACE inhibitors or &#x003b2; blockers, the results of autonomic dysfunction tests, and typical autonomic neuropathy symptoms (e.g. orthostatic hypotension, urinary incontinence, constipation) [<xref ref-type="bibr" rid="CR16">16</xref>] were among our variables. We used Microsoft Excel (Microsoft Japan, Tokyo, Japan) to arbitrarily assign a number from 1 to 252 to the patients and then enrolled the first 152 in the estimation group and the other 100 in the validation group. The diagnoses of the 252 patients are shown in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>, and our variables in Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>.<table-wrap id="Tab2"><label>Table&#x000a0;2</label><caption><p>Characteristics of the 252 patients and the study variables</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Variables</th><th align="left">Estimation group (<italic>n</italic>&#x000a0;=&#x000a0;152)</th><th align="left">Validation group (<italic>n</italic>&#x000a0;=&#x000a0;100)</th><th align="left">
<italic>p</italic> value</th></tr></thead><tbody><tr><td align="left">Age</td><td align="left">73.9&#x000a0;&#x000b1;&#x000a0;8.5</td><td align="left">72.5&#x000a0;&#x000b1;&#x000a0;10.4</td><td char="." align="char">0.24</td></tr><tr><td align="left">Gender (male:female)</td><td align="left">56:96</td><td align="left">43:57</td><td char="." align="char">0.36</td></tr><tr><td align="left">Diabetes mellitus</td><td align="left">29</td><td align="left">19</td><td char="." align="char">0.988</td></tr><tr><td align="left">ACE inhibitor or &#x003b2; blocker</td><td align="left">6</td><td align="left">8</td><td char="." align="char">0.169</td></tr><tr><td align="left">Autonomic neuropathy symptoms</td><td align="left">71</td><td align="left">42</td><td char="." align="char">0.462</td></tr><tr><td align="left">Autonomic dysfunction test</td><td align="left">48</td><td align="left">36</td><td char="." align="char">0.466</td></tr><tr><td align="left">Diagnosis (probable DLB :without DLB)</td><td align="left">48:104</td><td align="left">24:76</td><td char="." align="char">0.20</td></tr><tr><td align="left" colspan="4">MIBG scintigraphy</td></tr><tr><td align="left">&#x000a0;Early H/M ratio</td><td align="left">2.53&#x000a0;&#x000b1;&#x000a0;0.81</td><td align="left">2.64&#x000a0;&#x000b1;&#x000a0;0.88</td><td char="." align="char">0.28</td></tr><tr><td align="left">&#x000a0;Delayed H/M ratio</td><td align="left">2.48&#x000a0;&#x000b1;&#x000a0;1.07</td><td align="left">2.66&#x000a0;&#x000b1;&#x000a0;1.09</td><td char="." align="char">0.20</td></tr><tr><td align="left">&#x000a0;Washout rate</td><td align="left">39.8&#x000a0;&#x000b1;&#x000a0;17.2</td><td align="left">38.3&#x000a0;&#x000b1;&#x000a0;17.7</td><td char="." align="char">0.51</td></tr><tr><td align="left" colspan="4">Brain perfusion scintigraphy</td></tr><tr><td align="left">&#x000a0;Frontal lobe</td><td align="left">1.73&#x000a0;&#x000b1;&#x000a0;0.83</td><td align="left">1.76&#x000a0;&#x000b1;&#x000a0;0.76</td><td char="." align="char">0.80</td></tr><tr><td align="left">&#x000a0;Parietal lobe</td><td align="left">1.87&#x000a0;&#x000b1;&#x000a0;0.82</td><td align="left">1.78&#x000a0;&#x000b1;&#x000a0;0.93</td><td char="." align="char">0.42</td></tr><tr><td align="left">&#x000a0;Temporal lobe</td><td align="left">1.85&#x000a0;&#x000b1;&#x000a0;0.97</td><td align="left">1.72&#x000a0;&#x000b1;&#x000a0;0.69</td><td char="." align="char">0.23</td></tr><tr><td align="left">&#x000a0;Occipital lobe</td><td align="left">0.95&#x000a0;&#x000b1;&#x000a0;0.80</td><td align="left">0.82&#x000a0;&#x000b1;&#x000a0;0.70</td><td char="." align="char">0.18</td></tr><tr><td align="left">&#x000a0;Precentral gyrus</td><td align="left">1.37&#x000a0;&#x000b1;&#x000a0;0.59</td><td align="left">1.46&#x000a0;&#x000b1;&#x000a0;0.86</td><td char="." align="char">0.33</td></tr><tr><td align="left">&#x000a0;Postcentral gyrus</td><td align="left">1.58&#x000a0;&#x000b1;&#x000a0;0.74</td><td align="left">1.56&#x000a0;&#x000b1;&#x000a0;1.09</td><td char="." align="char">0.86</td></tr><tr><td align="left">Precuneus</td><td align="left">1.15&#x000a0;&#x000b1;&#x000a0;0.88</td><td align="left">1.02&#x000a0;&#x000b1;&#x000a0;0.75</td><td char="." align="char">0.22</td></tr><tr><td align="left">&#x000a0;Parahippocampus</td><td align="left">1.62&#x000a0;&#x000b1;&#x000a0;1.42</td><td align="left">1.43&#x000a0;&#x000b1;&#x000a0;0.96</td><td char="." align="char">0.24</td></tr><tr><td align="left">&#x000a0;Anterior cingulate</td><td align="left">1.53&#x000a0;&#x000b1;&#x000a0;0.78</td><td align="left">1.62&#x000a0;&#x000b1;&#x000a0;0.77</td><td char="." align="char">0.36</td></tr><tr><td align="left">&#x000a0;Posterior cingulate</td><td align="left">0.95&#x000a0;&#x000b1;&#x000a0;0.73</td><td align="left">0.82&#x000a0;&#x000b1;&#x000a0;0.57</td><td char="." align="char">0.14</td></tr><tr><td align="left">&#x000a0;Uncus</td><td align="left">1.59&#x000a0;&#x000b1;&#x000a0;1.16</td><td align="left">1.54&#x000a0;&#x000b1;&#x000a0;0.90</td><td char="." align="char">0.69</td></tr></tbody></table><table-wrap-foot><p>
<italic>H/M ratio</italic> heart/mediastinum ratio</p></table-wrap-foot></table-wrap></p><p>In estimation group, we identified the variables for predicting a diagnosis of DLB by univariate analysis. Then, we subjected all variables with a significant predictive value to multivariate forward stepwise regression analysis to identify independent predictors of probable DLB. Next, we constructed a predictive index, designated the combined index, by modeling the values of the independent variables and their coefficients of regression. The diagnostic value of the combined index was assessed by calculating the area under the receiver operating characteristic (ROC) curve for both patient groups. Diagnostic accuracy was evaluated by calculating sensitivity, specificity, positive and negative predictive value (PPV, NPV), and accuracy. The cut-off value of each index was based on the ROC curve to show the highest accuracy for the differentiation between probable and without DLB. The diagnostic accuracy of this index was then tested in validation group. Statistical analysis was with Stat View version 15.0 (SAS Institute Inc., Cary, NC, USA).</p><p>Using the cut-off values of the independent predictors obtained from estimation group analysis, we categorized validation group and created a decision tree to evaluate the diagnostic probability of probable and without DLB.</p></sec></sec><sec id="Sec7" sec-type="results"><title>Results</title><sec id="Sec8"><title>Combined index</title><p>As shown in Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>, the results of univariate analysis identified 10 variables as statistically significant (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.05). Subsequent multivariate forward stepwise regression analysis indicated that 3, the patient age, early H/M ratio, and parietal lobe hypo-perfusion, were independent predictors of probable DLB. Our formula for calculating the combined index for estimation group was:<table-wrap id="Tab3"><label>Table&#x000a0;3</label><caption><p>Variables associated with probable DLB in the estimation group (152 patients) by univariate and multivariate analysis</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Variables</th><th align="left" colspan="3">Univariate analysis</th><th align="left">Multivariate analysis</th></tr><tr><th align="left">Probable DLB (<italic>n</italic>&#x000a0;=&#x000a0;46)</th><th align="left">Without DLB (<italic>n</italic>&#x000a0;=&#x000a0;106)</th><th align="left">
<italic>p</italic> value</th><th align="left">
<italic>p</italic> value</th></tr></thead><tbody><tr><td align="left">Age</td><td align="left">76.8&#x000a0;&#x000b1;&#x000a0;6.3</td><td align="left">72.5&#x000a0;&#x000b1;&#x000a0;9.0</td><td char="." align="char">&#x0003c;0.001</td><td char="." align="char">&#x0003c;0.01</td></tr><tr><td align="left">Gender (male:female)</td><td align="left">22:32</td><td align="left">42 : 72</td><td char="." align="char">0.37</td><td align="left"/></tr><tr><td align="left">Diabetes mellitus</td><td align="left">7</td><td align="left">22</td><td char="." align="char">0.425</td><td align="left"/></tr><tr><td align="left">ACE inhibitor or &#x003b2; blocker</td><td align="left">2</td><td align="left">4</td><td char="." align="char">0.867</td><td align="left"/></tr><tr><td align="left">Autonomic neuropathy symptoms</td><td align="left">21</td><td align="left">50</td><td char="." align="char">0.863</td><td align="left"/></tr><tr><td align="left">Autonomic dysfunction test</td><td align="left">8 (<italic>n</italic>&#x000a0;=&#x000a0;14)</td><td align="left">15 (<italic>n</italic>&#x000a0;=&#x000a0;34)</td><td char="." align="char">0.412</td><td align="left"/></tr><tr><td align="left">&#x000a0;Early H/M ratio</td><td align="left">1.82&#x000a0;&#x000b1;&#x000a0;0.63</td><td align="left">2.85&#x000a0;&#x000b1;&#x000a0;0.67</td><td char="." align="char">&#x0003c;0.001</td><td char="." align="char">&#x0003c;0.01</td></tr><tr><td align="left">&#x000a0;Delay H/M ratio</td><td align="left">1.62&#x000a0;&#x000b1;&#x000a0;0.80</td><td align="left">2.87&#x000a0;&#x000b1;&#x000a0;0.94</td><td char="." align="char">&#x0003c;0.001</td><td char="." align="char">0.58</td></tr><tr><td align="left">&#x000a0;Washout rate (%)</td><td align="left">49.6&#x000a0;&#x000b1;&#x000a0;15.4</td><td align="left">35.2&#x000a0;&#x000b1;&#x000a0;16.0</td><td char="." align="char">&#x0003c;0.001</td><td char="." align="char">0.56</td></tr><tr><td align="left">&#x000a0;Frontal lobe</td><td align="left">1.95&#x000a0;&#x000b1;&#x000a0;0.98</td><td align="left">1.63&#x000a0;&#x000b1;&#x000a0;0.73</td><td char="." align="char">&#x0003c;0.05</td><td char="." align="char">0.41</td></tr><tr><td align="left">&#x000a0;Parietal lobe</td><td align="left">2.29&#x000a0;&#x000b1;&#x000a0;0.70</td><td align="left">1.66&#x000a0;&#x000b1;&#x000a0;0.79</td><td char="." align="char">&#x0003c;0.001</td><td char="." align="char">&#x0003c;0.01</td></tr><tr><td align="left">&#x000a0;Temporal lobe</td><td align="left">2.08&#x000a0;&#x000b1;&#x000a0;0.67</td><td align="left">1.74&#x000a0;&#x000b1;&#x000a0;1.06</td><td char="." align="char">&#x0003c;0.05</td><td char="." align="char">0.68</td></tr><tr><td align="left">&#x000a0;Occipital lobe</td><td align="left">1.16&#x000a0;&#x000b1;&#x000a0;0.84</td><td align="left">0.92&#x000a0;&#x000b1;&#x000a0;0.86</td><td char="." align="char">0.11</td><td align="left"/></tr><tr><td align="left">&#x000a0;Precentral gyrus</td><td align="left">1.47&#x000a0;&#x000b1;&#x000a0;0.56</td><td align="left">1.32&#x000a0;&#x000b1;&#x000a0;0.60</td><td char="." align="char">0.14</td><td align="left"/></tr><tr><td align="left">&#x000a0;Postcentral gyrus</td><td align="left">1.78&#x000a0;&#x000b1;&#x000a0;0.79</td><td align="left">1.49&#x000a0;&#x000b1;&#x000a0;0.70</td><td char="." align="char">&#x0003c;0.05</td><td char="." align="char">0.33</td></tr><tr><td align="left">&#x000a0;Precuneus</td><td align="left">1.51&#x000a0;&#x000b1;&#x000a0;0.99</td><td align="left">0.98&#x000a0;&#x000b1;&#x000a0;0.78</td><td char="." align="char">&#x0003c;0.001</td><td char="." align="char">0.16</td></tr><tr><td align="left">&#x000a0;Parahippocampas</td><td align="left">1.56&#x000a0;&#x000b1;&#x000a0;1.50</td><td align="left">1.65&#x000a0;&#x000b1;&#x000a0;1.39</td><td char="." align="char">0.74</td><td align="left"/></tr><tr><td align="left">&#x000a0;Anterior cingulate</td><td align="left">1.65&#x000a0;&#x000b1;&#x000a0;0.77</td><td align="left">1.47&#x000a0;&#x000b1;&#x000a0;0.78</td><td char="." align="char">0.19</td><td align="left"/></tr><tr><td align="left">&#x000a0;Posterior cingulate</td><td align="left">1.14&#x000a0;&#x000b1;&#x000a0;0.94</td><td align="left">0.86&#x000a0;&#x000b1;&#x000a0;0.59</td><td char="." align="char">&#x0003c;0.05</td><td char="." align="char">0.89</td></tr><tr><td align="left">&#x000a0;Uncus</td><td align="left">1.55&#x000a0;&#x000b1;&#x000a0;1.05</td><td align="left">1.60&#x000a0;&#x000b1;&#x000a0;1.21</td><td char="." align="char">0.79</td><td align="left"/></tr></tbody></table></table-wrap><disp-formula id="Equa"><alternatives><tex-math id="M1">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$- 4. 7 2 - 2. 4 8 \times {\text{early H}}/{\text{M}} + 1.0 7 \times {\text{parietal lobe hypo}} - {\text{perfusion}} + 0. 10 \times {\text{age}}$$\end{document}</tex-math><mml:math id="M2" display="block"><mml:mrow><mml:mo>-</mml:mo><mml:mn>4.72</mml:mn><mml:mo>-</mml:mo><mml:mn>2.48</mml:mn><mml:mo>&#x000d7;</mml:mo><mml:mrow><mml:mtext>early H</mml:mtext></mml:mrow><mml:mo stretchy="false">/</mml:mo><mml:mtext>M</mml:mtext><mml:mo>+</mml:mo><mml:mn>1.07</mml:mn><mml:mo>&#x000d7;</mml:mo><mml:mrow><mml:mtext>parietal lobe hypo</mml:mtext></mml:mrow><mml:mo>-</mml:mo><mml:mtext>perfusion</mml:mtext><mml:mo>+</mml:mo><mml:mn>0.10</mml:mn><mml:mo>&#x000d7;</mml:mo><mml:mtext>age</mml:mtext></mml:mrow></mml:math><graphic xlink:href="12149_2013_796_Article_Equa.gif" position="anchor"/></alternatives></disp-formula></p></sec><sec id="Sec9"><title>Diagnostic performance of the combined index</title><sec id="Sec10"><title>Estimation group</title><p>Significant variables of the combined index with respect to the diagnosis of probable DLB were the area under the ROC curve (AUC, 0.91), the early H/M ratio (0.87, <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.05), the parietal lobe hypoperfusion score (0.75, <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.01), and the patient age (0.63, <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001). Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref> presents the sensitivity (80&#x000a0;%), specificity (92&#x000a0;%), the PPV (82&#x000a0;%), NPV (91&#x000a0;%), and accuracy (88&#x000a0;%) at the selected cut-off values of these 4 indices and shows that the combined index yielded high diagnostic performance for probable DLB.<table-wrap id="Tab4"><label>Table&#x000a0;4</label><caption><p>Diagnostic accuracy of the 4 variables in the estimation group (<italic>n</italic>&#x000a0;=&#x000a0;152)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Variables</th><th align="left">Cut-off</th><th align="left">AUC (95&#x000a0;% CI)</th><th align="left">Sensitivity</th><th align="left">Specificity</th><th align="left">Accuracy</th><th align="left">PPV</th><th align="left">NPV</th></tr></thead><tbody><tr><td align="left">Combined index</td><td align="left">&#x0003e;0.03</td><td align="left">0.91 (0.84&#x02013;0.95)</td><td align="left">80</td><td align="left">92</td><td align="left">88</td><td align="left">82</td><td align="left">91</td></tr><tr><td align="left">Early H/M ratio</td><td align="left">&#x0003c;2.2</td><td align="left">0.87 (0.80&#x02013;0.92)</td><td align="left">85</td><td align="left">86</td><td align="left">85</td><td align="left">74</td><td align="left">92</td></tr><tr><td align="left">Parietal lobe hypoperfusion score</td><td align="left">&#x0003e;1.85</td><td align="left">0.75 (0.67&#x02013;0.82)</td><td align="left">73</td><td align="left">73</td><td align="left">73</td><td align="left">55</td><td align="left">85</td></tr><tr><td align="left">Age</td><td align="left">&#x0003e;70</td><td align="left">0.63 (0.55&#x02013;0.71)</td><td align="left">89</td><td align="left">35</td><td align="left">52</td><td align="left">39</td><td align="left">87</td></tr></tbody></table><table-wrap-foot><p>
<italic>PPV</italic> positive predictive value, <italic>NPV</italic> negative predictive value, <italic>H/M</italic> heart-to-mediastinum</p><p>Combined index vs. H/M, <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.05; combined index vs. parietal lobe hypoperfusion, <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.01; combined index vs. age, <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.001</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec11"><title>Validation group</title><p>The AUC of the combined index, the early H/M ratio, the parietal lobe hypoperfusion score, and the age were 0.95, 0.90 (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.05), 0.72 (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.01), and 0.73 (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.01), respectively. The diagnostic value of the combined index for probable DLB was similar to estimation group. Table&#x000a0;<xref rid="Tab5" ref-type="table">5</xref> shows the sensitivity (88&#x000a0;%), specificity (87&#x000a0;%), PPV (68&#x000a0;%), NPV (96&#x000a0;%), and accuracy (87&#x000a0;%) at the selected cut-off values. In this group also, the combined index yielded high diagnostic performance for probable DLB.<table-wrap id="Tab5"><label>Table&#x000a0;5</label><caption><p>Diagnostic accuracy of the 4 variables in the validation group (<italic>n</italic>&#x000a0;=&#x000a0;100)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Variables</th><th align="left">Cut-off</th><th align="left">AUC (95&#x000a0;% CI)</th><th align="left">Sensitivity</th><th align="left">Specificity</th><th align="left">Accuracy</th><th align="left">PPV</th><th align="left">NPV</th></tr></thead><tbody><tr><td align="left">Combined Index</td><td align="left">&#x0003e;0.03</td><td align="left">0.95 (0.88&#x02013;0.98)</td><td align="left">88</td><td align="left">87</td><td align="left">87</td><td align="left">68</td><td align="left">96</td></tr><tr><td align="left">Early H/M ratio</td><td align="left">&#x0003c;2.2</td><td align="left">0.90 (0.82&#x02013;0.95)</td><td align="left">83</td><td align="left">85</td><td align="left">84</td><td align="left">64</td><td align="left">94</td></tr><tr><td align="left">Parietal lobe hypoperfusion score</td><td align="left">&#x0003e;1.85</td><td align="left">0.72 (0.62&#x02013;0.80)</td><td align="left">63</td><td align="left">75</td><td align="left">72</td><td align="left">44</td><td align="left">87</td></tr><tr><td align="left">Age</td><td align="left">&#x0003e;70</td><td align="left">0.73 (0.63&#x02013;0.81)</td><td align="left">87</td><td align="left">45</td><td align="left">55</td><td align="left">33</td><td align="left">92</td></tr></tbody></table><table-wrap-foot><p>
<italic>PPV</italic> positive predictive value, <italic>NPV</italic> negative predictive value, <italic>H/M</italic> heart-to-mediastinum</p><p>Combined index vs. H/M, <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.05; combined index vs. parietal lobe hypoperfusion, <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.01; combined index vs. age, <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.01</p></table-wrap-foot></table-wrap></p></sec></sec><sec id="Sec12"><title>Diagnostic value of each index in validation group</title><p>Box plots of the combined index, the early H/M ratio, the parietal lobe hypoperfusion score, and the age in patients with probable and without DLB are shown in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>. Patients with probable DLB tended to be older and their parietal lobe hypoperfusion score was higher. We observed considerable overlap in patients with probable and without DLB. The early H/M ratio was significantly lower and the combined index was higher in patients with probable- than without DLB. Compared with the other indices, in the combined index, there was a relatively small overlap between estimation group and 2, indicating that it was the most useful index for the diagnosis of DLB.<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Predictive accuracy of the combined index in the validation group. Box plots of <bold>a</bold> the patient age, <bold>b</bold> the early H/M ratio, <bold>c</bold> the parietal lobe hypoperfusion score, and <bold>d</bold> the combined index are shown for patients with probable and without DLB. The combined index, the parietal lobe hypo-perfusion, and the age were higher and the Early H/M ratio was lower in patients with probable- than without DLB. There was the relatively smallest overlap between the groups with respect to the combined index</p></caption><graphic xlink:href="12149_2013_796_Fig1_HTML" id="MO2"/></fig></p></sec><sec id="Sec13"><title>Decision tree using independent predictors in validation group</title><p>Using the cut-off value of the 3 independent predictors of probable DLB (early H/M ratio, parietal lobe hypoperfusion score, age) calculated from estimation group, we categorized patients in validation group. The total number of patients with probable and without DLB and PPV is shown in Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref> as is the number of patients with PD in each category.<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Decision tree using independent predictors in the validation group. Using the cut-off value of the 3 independent predictors of probable DLB (early H/M ratio, parietal lobe hypoperfusion score, age) calculated from estimation group, we categorized patients in validation group. The total number of patients with probable and without DLB and PPV is shown</p></caption><graphic xlink:href="12149_2013_796_Fig2_HTML" id="MO3"/></fig></p></sec></sec><sec id="Sec14" sec-type="discussion"><title>Discussion</title><p>A differential diagnosis of dementia can be difficult in the early stage as there is considerable overlap in the clinical features of different types of the disease. However, objective and accurate information regarding vital functions can be obtained with <sup>123</sup>I-IMP brain perfusion SPECT and <sup>123</sup>I-MIBG myocardial scintigraphy studies.</p><p>A decrease in the H/M ratio on <sup>123</sup>I-MIBG myocardial scintigraphy images was reported as an independent predictor of DLB [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR17">17</xref>&#x02013;<xref ref-type="bibr" rid="CR19">19</xref>] and is included in the current guidelines to diagnose DLB. Yoshita et al. [<xref ref-type="bibr" rid="CR19">19</xref>] found that at a cut-off value of 1.68, the H/M ratio was 100&#x000a0;% sensitive and specific for the differentiation between DLB and AD. Estorch et al. [<xref ref-type="bibr" rid="CR20">20</xref>] reported that at a cut-off value of 1.36, this ratio could distinguish between DLB and other dementias; the sensitivity and specificity were 94 and 96&#x000a0;%, respectively. However, similar finding was obtained in PD patients. We found that the diagnostic performance of the early H/M ratio was relatively low (sensitivity 83&#x000a0;%, specificity of 85&#x000a0;%), probably because our patients with without DLB included 11 PD patients. The PD patients were individuals who presented with symptoms of dementia in the course of this study; based on the 1-year rule [<xref ref-type="bibr" rid="CR21">21</xref>], they were diagnosed as having dementia with PD (PDD).</p><p>The differentiation between DLB and PDD is difficult and both dementias are thought to belong in the spectrum of Lewy body disease (LBD). From a pathological perspective, the deposition of phosphorylated &#x003b1;-synuclein aggregates in the substantia nigra and the corresponding selective damage to the dopamine system are severe in PDD. On the other hand, as cerebral lesions are thought to be characteristic in DLB, the pathogenic mechanisms involved in DLB and PDD are slightly different [<xref ref-type="bibr" rid="CR22">22</xref>]. According to Lippa et al. [<xref ref-type="bibr" rid="CR23">23</xref>], it is appropriate to distinguish between DLB and PDD based on their different clinical symptoms and rate of progression. Therefore, we assigned PD patients to the without-DLB group. This may explain why the performance of the H/M ratio on our <sup>123</sup>I-MIBG myocardial scintigraphy images was not much better than in earlier reports. With respect to LBD that includes DLB and PDD, clinical techniques that closely study and directly detect the distribution and degree of the cerebral pathology are needed.</p><p>On brain perfusion SPECT, patients with DLB manifest occipital hypoperfusion, a diagnostic factor cited in the consensus guidelines [<xref ref-type="bibr" rid="CR8">8</xref>]. However, SPECT findings do not differentiate between DLB and AD as their reported sensitivity ranges from only 65&#x02013;74&#x000a0;% [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. Although occipital hypoperfusion has been reported to help in the differentiation between DLB and AD, its specific diagnostic value with respect to DLB and dementias other than AD has not been documented. We found that the average perfusion of the occipital lobe was decreased not only in patients with probable DLB (severity score 1.16&#x000a0;&#x000b1;&#x000a0;0.84) but also in patients with without DLB who presented with VaD and other dementia types (severity score 0.92&#x000a0;&#x000b1;&#x000a0;0.86). Thus, occipital hypoperfusion may not be a useful factor for the differentiation between probable and without DLB including not only AD but also other dementias. Among the <sup>123</sup>I-IMP brain perfusion SPECT predictors in this study, multivariate forward stepwise regression analysis identified parietal lobe hypoperfusion as an independent predictor. Limiting the targeted diseases to DLB and AD as was done in earlier studies would not have identified parietal lobe hypoperfusion as an independent predictor. Although we cannot rule out the possibility that patients with dementing disorders other than AD were included in our study population, there are few diseases other than AD with a specific decrease in the flow of blood to the parietal lobe. Therefore, we propose that parietal lobe hypoperfusion is a useful indicator for diseases other than AD. We consider parietal lobe hypoperfusion to be of greater diagnostic value than occipital lobe hypoperfusion because of its higher incidence in patients with probable DLB.</p><p>We used both <sup>123</sup>I-IMP brain perfusion SPECT and <sup>123</sup>I-MIBG myocardial scintigraphy to obtain a differential diagnosis of DLB among various dementing disorders. Although the usefulness and diagnostic performance of these imaging modalities have been evaluated individually, there are only two published studies that combined both modalities. Hanyu et al. [<xref ref-type="bibr" rid="CR9">9</xref>] who compared the clinical value of brain perfusion SPECT and MIBG myocardial scintigraphy in DLB and AD patients reported that the H/M ratio was decreased in all 19 of their DLB patients; only 14 manifested occipital hypoperfusion. They concluded that MIBG myocardial scintigraphy may be a powerful diagnostic tool when a differential diagnosis of DLB or AD based on brain perfusion SPECT findings is difficult. Tateno et al. [<xref ref-type="bibr" rid="CR10">10</xref>] found that 24 of 25 patients with dementia manifested a decreased cardiac MIBG uptake on delayed images (obtained 3&#x000a0;h post-injection); they observed occipital hypoperfusion in only 17 patients (68&#x000a0;%).</p><p>To surmount the limitations of <sup>123</sup>I-MIBG cardiac scintigraphy and <sup>123</sup>I-IMP brain perfusion SPECT, we developed a formula to calculate the combined index for the differentiation of probable DLB from without DLB. We used the combined index, calculated by combining the values obtained in estimation group for the early H/M ratio, the parietal lobe hypoperfusion score, and the age to predict DLB. We then assessed its diagnostic value in validation group. We document that the combined index was more accurate for diagnosing probable DLB at an AUC of 0.94 than the early H/M ratio (0.90), the parietal lobe hypoperfusion score (0.69), or the patient age (0.72).</p><p>As shown in Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>, when evaluated with <sup>123</sup>I-MIBG cardiac scintigraphy alone, the PPV for a diagnosis of probable DLB was 70&#x000a0;% in patients with an early H/M ratio &#x02264;2.2. On the other hand, when we included the parietal lobe hypoperfusion score obtained on <sup>123</sup>I-IMP brain perfusion SPECT images, the PPV rose to 90&#x000a0;%. The PPV for probable DLB increased from 5 to 15&#x000a0;% when we included the parietal lobe hypoperfusion score in patients with an early H/M ratio &#x02265;2.2. Although the differentiation between PD and DLB is difficult based on MIBG scintigraphy findings alone, a correct diagnosis can be obtained when brain perfusion SPECT images show parietal lobe hypoperfusion since PD patients manifest a non-specific pattern of decreased cerebral blood flow. In fact, as shown in Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>, of the 11 PD patients, we identified 7 (64&#x000a0;%) as without DLB when we used 1.85 as the cut-off value for parietal lobe hypoperfusion.</p><p>On the other hand, despite their decreased early H/M ratio, 4 patients with probable DLB (15&#x000a0;%) did not present with parietal lobe hypoperfusion on <sup>123</sup>I-IMP brain perfusion SPECT images. We attribute this to pure autonomic failure (LBD-P: Lewy body disease parkinsonism) due to autonomic neuropathy as the main condition. There were 3 patients with probable DLB (12&#x000a0;%) who manifested parietal lobe hypoperfusion although <sup>123</sup>I-MIBG cardiac scintigraphy showed no abnormality. We think that in these patients cognitive impairment resulted in a diagnosis of Lewy body disease dementia (LBD-D) and that treatment reversed their autonomic dysfunction. In patients with probable DLB, factors such as parkinsonism, cognitive impairment, and autonomic neuropathy, and their main symptoms may result in different findings on <sup>123</sup>I-MIBG cardiac scintigraphy and <sup>123</sup>I-IMP brain perfusion SPECT images.</p><p><sup>123</sup>I-MIBG cardiac scintigraphy and <sup>123</sup>I-IMP brain perfusion SPECT can yield false-positive as well as false-negative results in patients with diabetes mellitus, heart failure, and in patients taking medications (scintigraphy) and in patients with cerebral vascular disorders and atrophy (SPECT). To compensate for these shortcomings, we recommend the acquisition of both <sup>123</sup>I-MIBG cardiac scintigraphy- and <sup>123</sup>I-IMP brain perfusion SPECT studies.</p><p>We attribute the high diagnostic performance in our study in part to the superiority of <sup>123</sup>I-IMP brain perfusion SPECT for the discrimination between DLB and PD and to the superior performance of <sup>123</sup>I-MIBG cardiac scintigraphy in the discrimination between DLB and AD.</p></sec><sec id="Sec15"><title>Limitations</title><p>Our study has some limitations. First, the diagnoses were not confirmed by autopsy but based on the careful interpretation of clinical and imaging findings. While we are carrying out follow-up imaging studies, postmortem findings are needed to confirm the presence of pathological changes in abnormally perfused areas. Second, in patients treated for autonomic dysfunction, the results of <sup>123</sup>I-MIBG cardiac scintigraphy may fluctuate. We encountered 3 patients with probable DLB (12&#x000a0;%) in whom <sup>123</sup>I-MIBG cardiac scintigraphy showed no abnormality; however, we did not have pre- and post-treatment <sup>123</sup>I-MIBG cardiac scintigraphy studies to evaluate the potential effects of treatment. Third, although <sup>123</sup>I-MIBG cardiac scintigraphy indicates autonomic dysfunction that is likely in DLB and PD, it is necessary to verify that it is superior to far less expensive clinical tests. In our retrospective study, the results of autonomic function tests were not useful for a differential diagnosis of probable and without DLB. Since not all patients had undergone these tests prior to their treatment, the number of evaluable patients was limited, and accurate comparisons were not possible.</p><p>Finally, the use of both <sup>123</sup>I-MIBG cardiac scintigraphy and <sup>123</sup>I-IMP brain perfusion SPECT raises economic and radiation exposure concerns. Either test can yield a positive result in the early stages of DLB as there are various pathogenic forms, and false-positive and false-negative results are shown by scintigraphy. Therefore, we recommend the combination of both imaging modalities to improve diagnostic performance at least in patients whose conventional tests lead to the suspicion of DLB.</p></sec><sec id="Sec16" sec-type="conclusion"><title>Conclusion</title><p>DLB has been reported to be the second most common type of degenerative dementia. However, it is often under-diagnosed and its discrimination from other types of dementia is very difficult, especially at its early stages. Since DLB results in specific impairments and functional disabilities, its early and accurate diagnosis is very important for a better prognosis and neuroimaging- and MIBG myocardial scintigraphy studies play important roles. Further research is needed to establish their clinical usefulness.</p></sec></body><back><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKeith</surname><given-names>I</given-names></name><name><surname>Mintzer</surname><given-names>J</given-names></name><name><surname>Aarsland</surname><given-names>D</given-names></name><name><surname>Burn</surname><given-names>D</given-names></name><name><surname>Chiu</surname><given-names>H</given-names></name><name><surname>Cohen-Mansfield</surname><given-names>J</given-names></name><etal/></person-group><article-title>Dementia with Lewy bodies</article-title><source>Lancet Neurol</source><year>2004</year><volume>3</volume><issue>1</issue><fpage>19</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(03)00619-7</pub-id><pub-id pub-id-type="pmid">14693108</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burgio</surname><given-names>L</given-names></name></person-group><article-title>Interventions for the behavioral complications of Alzheimer&#x02019;s disease: behavioral approaches</article-title><source>Int Psychogeriatr</source><year>1996</year><volume>8</volume><issue>Suppl 1</issue><fpage>45</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1017/S1041610296003079</pub-id><pub-id pub-id-type="pmid">8934265</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaufer</surname><given-names>DI</given-names></name><name><surname>Cummings</surname><given-names>JL</given-names></name><name><surname>Christine</surname><given-names>D</given-names></name><name><surname>Bray</surname><given-names>T</given-names></name><name><surname>Castellon</surname><given-names>S</given-names></name><name><surname>Masterman</surname><given-names>D</given-names></name><etal/></person-group><article-title>Assessing the impact of neuropsychiatric symptoms in Alzheimer&#x02019;s disease: the Neuropsychiatric Inventory Caregiver Distress Scale</article-title><source>J Am Geriatr Soc</source><year>1998</year><volume>46</volume><issue>2</issue><fpage>210</fpage><lpage>215</lpage><pub-id pub-id-type="pmid">9475452</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luis</surname><given-names>CA</given-names></name><name><surname>Barker</surname><given-names>WW</given-names></name><name><surname>Gajaraj</surname><given-names>K</given-names></name><name><surname>Harwood</surname><given-names>D</given-names></name><name><surname>Petersen</surname><given-names>R</given-names></name><name><surname>Kashuba</surname><given-names>A</given-names></name><etal/></person-group><article-title>Sensitivity and specificity of three clinical criteria for dementia with Lewy bodies in an autopsy-verified sample</article-title><source>Int J Geriatr Psychiatry</source><year>1999</year><volume>14</volume><issue>7</issue><fpage>526</fpage><lpage>533</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1099-1166(199907)14:7&#x0003c;526::AID-GPS965&#x0003e;3.0.CO;2-0</pub-id><pub-id pub-id-type="pmid">10440972</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKeith</surname><given-names>IG</given-names></name><name><surname>Ballard</surname><given-names>CG</given-names></name><name><surname>Perry</surname><given-names>RH</given-names></name><name><surname>Ince</surname><given-names>PG</given-names></name><name><surname>O&#x02019;Brien</surname><given-names>JT</given-names></name><name><surname>Neill</surname><given-names>D</given-names></name><etal/></person-group><article-title>Prospective validation of consensus criteria for the diagnosis of dementia with Lewy bodies</article-title><source>Neurology</source><year>2000</year><volume>54</volume><issue>5</issue><fpage>1050</fpage><lpage>1058</lpage><pub-id pub-id-type="doi">10.1212/WNL.54.5.1050</pub-id><pub-id pub-id-type="pmid">10720273</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holmes</surname><given-names>C</given-names></name><name><surname>Cairns</surname><given-names>N</given-names></name><name><surname>Lantos</surname><given-names>P</given-names></name><name><surname>Mann</surname><given-names>A</given-names></name></person-group><article-title>Validity of current clinical criteria for Alzheimer&#x02019;s disease, vascular dementia and dementia with Lewy bodies</article-title><source>Br J Psychiatry</source><year>1999</year><volume>174</volume><fpage>45</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1192/bjp.174.1.45</pub-id><pub-id pub-id-type="pmid">10211150</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mega</surname><given-names>MS</given-names></name><name><surname>Masterman</surname><given-names>DL</given-names></name><name><surname>Benson</surname><given-names>DF</given-names></name><name><surname>Vinters</surname><given-names>HV</given-names></name><name><surname>Tomiyasu</surname><given-names>U</given-names></name><name><surname>Craig</surname><given-names>AH</given-names></name><etal/></person-group><article-title>Dementia with Lewy bodies: reliability and validity of clinical and pathologic criteria</article-title><source>Neurology</source><year>1996</year><volume>47</volume><issue>6</issue><fpage>1403</fpage><lpage>1409</lpage><pub-id pub-id-type="doi">10.1212/WNL.47.6.1403</pub-id><pub-id pub-id-type="pmid">8960718</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Firbank</surname><given-names>MJ</given-names></name><name><surname>Burn</surname><given-names>DJ</given-names></name><name><surname>McKeith</surname><given-names>IG</given-names></name><name><surname>O&#x02019;Brien</surname><given-names>JT</given-names></name></person-group><article-title>Longitudinal study of cerebral blood flow SPECT in Parkinson&#x02019;s disease with dementia, and dementia with Lewy bodies</article-title><source>Int J Geriatr Psychiatry</source><year>2005</year><volume>20</volume><issue>8</issue><fpage>776</fpage><lpage>782</lpage><pub-id pub-id-type="doi">10.1002/gps.1359</pub-id><pub-id pub-id-type="pmid">16035122</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanyu</surname><given-names>H</given-names></name><name><surname>Shimizu</surname><given-names>S</given-names></name><name><surname>Hirao</surname><given-names>K</given-names></name><name><surname>Kanetaka</surname><given-names>H</given-names></name><name><surname>Iwamoto</surname><given-names>T</given-names></name><name><surname>Chikamori</surname><given-names>T</given-names></name><etal/></person-group><article-title>Comparative value of brain perfusion SPECT and [(123)I]MIBG myocardial scintigraphy in distinguishing between dementia with Lewy bodies and Alzheimer&#x02019;s disease</article-title><source>Eur J Nucl Med Mol Imaging</source><year>2006</year><volume>33</volume><issue>3</issue><fpage>248</fpage><lpage>253</lpage><pub-id pub-id-type="doi">10.1007/s00259-005-1921-x</pub-id><pub-id pub-id-type="pmid">16328506</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tateno</surname><given-names>M</given-names></name><name><surname>Kobayashi</surname><given-names>S</given-names></name><name><surname>Shirasaka</surname><given-names>T</given-names></name><name><surname>Furukawa</surname><given-names>Y</given-names></name><name><surname>Fujii</surname><given-names>K</given-names></name><name><surname>Morii</surname><given-names>H</given-names></name><etal/></person-group><article-title>Comparison of the usefulness of brain perfusion SPECT and MIBG myocardial scintigraphy for the diagnosis of dementia with Lewy bodies</article-title><source>Dement Geriatr Cogn Disord</source><year>2008</year><volume>26</volume><issue>5</issue><fpage>453</fpage><lpage>457</lpage><pub-id pub-id-type="doi">10.1159/000165918</pub-id><pub-id pub-id-type="pmid">18974648</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKeith</surname><given-names>IG</given-names></name></person-group><article-title>Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop</article-title><source>J Alzheimers Dis</source><year>2006</year><volume>9</volume><issue>3 Suppl</issue><fpage>417</fpage><lpage>423</lpage><pub-id pub-id-type="pmid">16914880</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hattori</surname><given-names>N</given-names></name><name><surname>Schwaiger</surname><given-names>M</given-names></name></person-group><article-title>Metaiodobenzylguanidine scintigraphy of the heart: what have we learnt clinically?</article-title><source>Eur J Nucl Med</source><year>2000</year><volume>27</volume><issue>1</issue><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1007/s002590050505</pub-id><pub-id pub-id-type="pmid">10654140</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Minoshima</surname><given-names>S</given-names></name><name><surname>Berger</surname><given-names>KL</given-names></name><name><surname>Lee</surname><given-names>KS</given-names></name><name><surname>Mintun</surname><given-names>MA</given-names></name></person-group><article-title>An automated method for rotational correction and centering of three-dimensional functional brain images</article-title><source>J Nucl Med</source><year>1992</year><volume>33</volume><issue>8</issue><fpage>1579</fpage><lpage>1585</lpage><pub-id pub-id-type="pmid">1634959</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Minoshima</surname><given-names>S</given-names></name><name><surname>Frey</surname><given-names>KA</given-names></name><name><surname>Koeppe</surname><given-names>RA</given-names></name><name><surname>Foster</surname><given-names>NL</given-names></name><name><surname>Kuhl</surname><given-names>DE</given-names></name></person-group><article-title>A diagnostic approach in Alzheimer&#x02019;s disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET</article-title><source>J Nucl Med</source><year>1995</year><volume>36</volume><issue>7</issue><fpage>1238</fpage><lpage>1248</lpage><pub-id pub-id-type="pmid">7790950</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mizumura</surname><given-names>S</given-names></name><name><surname>Kumita</surname><given-names>S</given-names></name><name><surname>Cho</surname><given-names>K</given-names></name><name><surname>Ishihara</surname><given-names>M</given-names></name><name><surname>Nakajo</surname><given-names>H</given-names></name><name><surname>Toba</surname><given-names>M</given-names></name><etal/></person-group><article-title>Development of quantitative analysis method for stereotactic brain image: assessment of reduced accumulation in extent and severity using anatomical segmentation</article-title><source>Ann Nucl Med</source><year>2003</year><volume>17</volume><issue>4</issue><fpage>289</fpage><lpage>295</lpage><pub-id pub-id-type="doi">10.1007/BF02988523</pub-id><pub-id pub-id-type="pmid">12932111</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horimoto</surname><given-names>Y</given-names></name><name><surname>Matsumoto</surname><given-names>M</given-names></name><name><surname>Akatsu</surname><given-names>H</given-names></name><name><surname>Ikari</surname><given-names>H</given-names></name><name><surname>Kojima</surname><given-names>K</given-names></name><name><surname>Yamamoto</surname><given-names>T</given-names></name><etal/></person-group><article-title>Autonomic dysfunctions in dementia with Lewy bodies</article-title><source>J Neurol</source><year>2003</year><volume>250</volume><issue>5</issue><fpage>530</fpage><lpage>533</lpage><pub-id pub-id-type="doi">10.1007/s00415-003-1029-9</pub-id><pub-id pub-id-type="pmid">12736730</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lobotesis</surname><given-names>K</given-names></name><name><surname>Fenwick</surname><given-names>JD</given-names></name><name><surname>Phipps</surname><given-names>A</given-names></name><name><surname>Ryman</surname><given-names>A</given-names></name><name><surname>Swann</surname><given-names>A</given-names></name><name><surname>Ballard</surname><given-names>C</given-names></name><etal/></person-group><article-title>Occipital hypoperfusion on SPECT in dementia with Lewy bodies but not AD</article-title><source>Neurology</source><year>2001</year><volume>56</volume><issue>5</issue><fpage>643</fpage><lpage>649</lpage><pub-id pub-id-type="doi">10.1212/WNL.56.5.643</pub-id><pub-id pub-id-type="pmid">11245717</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pasquier</surname><given-names>J</given-names></name><name><surname>Michel</surname><given-names>BF</given-names></name><name><surname>Brenot-Rossi</surname><given-names>I</given-names></name><name><surname>Hassan-Sebbag</surname><given-names>N</given-names></name><name><surname>Sauvan</surname><given-names>R</given-names></name><name><surname>Gastaut</surname><given-names>JL</given-names></name></person-group><article-title>Value of (99m)Tc-ECD SPET for the diagnosis of dementia with Lewy bodies</article-title><source>Eur J Nucl Med Mol Imaging</source><year>2002</year><volume>29</volume><issue>10</issue><fpage>1342</fpage><lpage>1348</lpage><pub-id pub-id-type="doi">10.1007/s00259-002-0919-x</pub-id><pub-id pub-id-type="pmid">12271417</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshita</surname><given-names>M</given-names></name><name><surname>Taki</surname><given-names>J</given-names></name><name><surname>Yamada</surname><given-names>M</given-names></name></person-group><article-title>A clinical role for [(123)I]MIBG myocardial scintigraphy in the distinction between dementia of the Alzheimer&#x02019;s-type and dementia with Lewy bodies</article-title><source>J Neurol Neurosurg Psychiatry</source><year>2001</year><volume>71</volume><issue>5</issue><fpage>583</fpage><lpage>588</lpage><pub-id pub-id-type="doi">10.1136/jnnp.71.5.583</pub-id><pub-id pub-id-type="pmid">11606666</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Estorch</surname><given-names>M</given-names></name><name><surname>Camacho</surname><given-names>V</given-names></name><name><surname>Paredes</surname><given-names>P</given-names></name><name><surname>Rivera</surname><given-names>E</given-names></name><name><surname>Rodriguez-Revuelto</surname><given-names>A</given-names></name><name><surname>Flotats</surname><given-names>A</given-names></name><etal/></person-group><article-title>Cardiac (123)I-metaiodobenzylguanidine imaging allows early identification of dementia with Lewy bodies during life</article-title><source>Eur J Nucl Med Mol Imaging</source><year>2008</year><volume>35</volume><issue>9</issue><fpage>1636</fpage><lpage>1641</lpage><pub-id pub-id-type="doi">10.1007/s00259-008-0828-8</pub-id><pub-id pub-id-type="pmid">18509631</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKeith</surname><given-names>IG</given-names></name><name><surname>Galasko</surname><given-names>D</given-names></name><name><surname>Kosaka</surname><given-names>K</given-names></name><name><surname>Perry</surname><given-names>EK</given-names></name><name><surname>Dickson</surname><given-names>DW</given-names></name><name><surname>Hansen</surname><given-names>LA</given-names></name><etal/></person-group><article-title>Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop</article-title><source>Neurology</source><year>1996</year><volume>47</volume><issue>5</issue><fpage>1113</fpage><lpage>1124</lpage><pub-id pub-id-type="doi">10.1212/WNL.47.5.1113</pub-id><pub-id pub-id-type="pmid">8909416</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Orimo</surname><given-names>S</given-names></name><name><surname>Takahashi</surname><given-names>A</given-names></name><name><surname>Uchihara</surname><given-names>T</given-names></name><name><surname>Mori</surname><given-names>F</given-names></name><name><surname>Kakita</surname><given-names>A</given-names></name><name><surname>Wakabayashi</surname><given-names>K</given-names></name><etal/></person-group><article-title>Degeneration of cardiac sympathetic nerve begins in the early disease process of Parkinson&#x02019;s disease</article-title><source>Brain Pathol</source><year>2007</year><volume>17</volume><issue>1</issue><fpage>24</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1111/j.1750-3639.2006.00032.x</pub-id><pub-id pub-id-type="pmid">17493034</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lippa</surname><given-names>CF</given-names></name><name><surname>Duda</surname><given-names>JE</given-names></name><name><surname>Grossman</surname><given-names>M</given-names></name><name><surname>Hurtig</surname><given-names>HI</given-names></name><name><surname>Aarsland</surname><given-names>D</given-names></name><name><surname>Boeve</surname><given-names>BF</given-names></name><etal/></person-group><article-title>DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers</article-title><source>Neurology</source><year>2007</year><volume>68</volume><issue>11</issue><fpage>812</fpage><lpage>819</lpage><pub-id pub-id-type="doi">10.1212/01.wnl.0000256715.13907.d3</pub-id><pub-id pub-id-type="pmid">17353469</pub-id></element-citation></ref></ref-list></back></article>